Pantoprazol Ametas (Pantoprazole)

Pantoprazol Ametas is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates ulcer healing in the oesophagus.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours.
• Peptic ulcer disease (duodenal and gastric): supports ulcer healing and reduces recurrence risk.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump in its active state, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Pantoprazol Ametas may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: loose stools without blood.
• Nausea: feeling of queasiness.
• Abdominal pain: mild cramping.
• Flatulence: increased intestinal gas.
• Constipation: infrequent, hard stools.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile infection: persistent watery diarrhoea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Liver enzyme elevation: abnormal liver function tests.
• Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Pantoprazol Ametas should be used with caution in specific clinical situations.

• Assess renal function: adjust use in severe renal impairment.
• Monitor for infections: prolonged acid suppression may increase risk of gastrointestinal infections.
• Evaluate bone health: long‑term therapy may affect calcium absorption.
• Review concomitant medications: potential for altered absorption of drugs requiring acidic pH.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Pantoprazol Ametas can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric ppH.
• HIV protease inhibitors (ritonavir, atazanavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation.
• Methotrexate: reduced renal clearance may raise serum levels.
• Digoxin: slight increase in serum concentration.
• Iron supplements: decreased absorption; separate dosing by at least 2 hours.